Thierry André, MD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Metastatic Disease

June 01, 2020 By The ASCO Post Staff

Thierry André, MD, of Hôpital Saint-Antoine, discusses the phase III results from KEYNOTE-177, which showed that, compared with standard chemotherapy of FOLFOX or FOLFIRI, pembrolizumab doubled median progression-free survival, from 8.2 months to 16.5 months, in patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract LBA4).

Related Content